Premaitha Share Discussion Threads

[thinkbig?] 19/5/2017 15:20

First good announcement Now that's revenue enhancing. 100% good news with substance. Other countries will follow now. In the EU Don't know what Britex will have on the company.But it's in right direction

[bean02] 19/5/2017 14:57

Buys showing as sells

[jonnycj] 19/5/2017 14:31

Announcement on France

[slartybartfaster] 17/5/2017 16:52

shoosh, dont mention hsr or you will wake the tw trolls.

[2vdm] 17/5/2017 11:41

Just posted as a Buy again on Hot Stock Rockets. They point out not to bet the farm on it, but I agree and at this price I think it's worth getting in for the longer haul. Interesting year ahead.

[slartybartfaster] 17/5/2017 10:34

Dip my toe into the water today just because mickey mouse troll campaign. my logic is he is wrong more often than right especially where his troll campaign is aimed at uncle tommy.

[gooosed] 16/5/2017 16:33

Philburt - Not quite on target then after all

[philburt] 16/5/2017 14:16

It's quite funny seeing only one half of all these debates. The sensible half, that is. The other, less lucid half, has long since been filtered...... lol

[on target] 16/5/2017 13:50

Which court case? There seems to be a conveyor belt of them here!

[2vdm] 16/5/2017 12:11

so do you conclude that this is a Buy then?

[hjb1] 16/5/2017 11:26

in case anyone missed it, this is a reply I had from Hardman's a few months ago when I asked the question about the court case.

Dear Mr....
First, I have undertaken a complete review of the patent situation in Europe and came to the conclusion that Illumina has a very weak case. However, I have not been allowed to publish this work because the lawyers stated that I had supplied the entire defense and did not want this in the public domain. So I think that Premaitha has a good chance of winning its case. However, I am also aware of time and costs and could understand a situation where Premaitha settles out of court on the right terms - ie close to the royalty rate that is paid by its 'friends' as opposed to the $75 per test that Illumina wants to charge Great Ormond Street Hospital.

Notwithstanding this, Illumina's patents are not covered in several territories in SE Asia. This provides two things. First, it means that IONA can be used in these markets without risk of patent infringement. Secondly, it means that maternal blood samples can be spun down and analysed in, say Europe, and the results sent to Taiwan for analysis (as Yourgene is currently doing), thus avoiding Illumina's European patents. Therefore, I feel that this is a realistic possibility in the unlikely event that the Illumina patents are upheld.

I hope that this helps.

Dr Martin Hall
Life Sciences Team

[hjb1] 16/5/2017 11:06

Germany...maybe this could set a precedent;
Dimissed by the supreme court...could bode well..

[hjb1] 16/5/2017 11:03

the share price will not do much until the court case is settled. MM having some fun it seems.

[deanroberthunt] 16/5/2017 10:52

it's that superb the share price is now flat

[deanroberthunt] 16/5/2017 10:51

Clearly, not just here, and especially in sport, the word "GREAT" is greatly overused...and some....

[ngen yap] 16/5/2017 08:23

Superb update indeed.

I like the pro-forma revenue of £5m excluding Genoma. And that like-for-like revenue growth is 250%. If this trend continues, even at 100%, we should hit Hardman's target of £13m in 2017/2018, which means we are on track.

Now, let's get the litigation out of the way (or settlement), and we should be on a real winner.

[hamidahamida] 16/5/2017 08:00

Awesome TU

[michaelmouse] 16/5/2017 07:56

See post 4593 and the company is valued at £33m. A positive bargain LOL.

Aimho of course.

[michaelmouse] 16/5/2017 07:53

"Its a brilliant update...."

LOL.

[whites123] 16/5/2017 07:49

Its a brilliant update....

No "Good" or "mediocre" about it.

Its great. :-)

When I was chatting to them last week the emphasis is always on the people.
They always bounce off each other and out of the closed period (Unless deals are progressing) then I have been reliably informed that certain persons at NIPT are chomping at the bit to buy some stock.

Geographic expansion

The geographic spread of customers has continued at a rapid rate, as per recent announcements, with distributors appointed in the Middle East, Southern Europe and recently in Croatia. Yourgene has a broad installed base across Asia which is also growing significantly (see below).

The IONA® test is now an established leading NIPT solution in the UK, France and the Middle East and its presence is growing in other markets. There are further installations scheduled in the next quarter in France, Italy, Taiwan, South East Asia, the Middle East, South Africa and Northern Europe with a strong forward pipeline. Several of these installations will be on Thermo Fisher's latest S5 instrument platform, on which the IONA® test has now been validated.

Furthermore, the first IONA® test laboratory installation for the major European diagnostics services customer announced in February 2017 is on track for June 2017, with a further installation for the same customer due later this year.

A pre-requisite for geographic expansion in many countries is the registration of products prior to sale. National regulatory processes are variable in complexity and time but are generally lengthy for significant markets. Premaitha has completed registration for the IONA® test in the EU (CE-mark) and three other countries to date, and is well-advanced in registering the IONA® test in Canada, Mexico, Brazil, Saudi Arabia, Malaysia and Vietnam. Registration in China is expected to commence later in 2017/early 2018 once a suitable partner has been selected.

[hjb1] 16/5/2017 07:47

not far off track with Hardman's last report of £3.2m rev so NO surprises.It would not have mattered if rev was £20m as some would still deramp eh?? lmao!